News – Cellestial Health

Cellestial Health Presents at the Venture Summit West, California

18th of June 2026; Mountain View, California, USACellestial Health, an innovative pharmaceutical development company offering a paradigm shift approach to Parkinson’s treatments, announces its selection and participation at the 2025 Venture Summit West, which took place June 16–17, 2025 at the Computer History Museun in Mountain View, Silicon Valley. Hosted by youngStartup Ventures, the summit is recognized as…

#Killer50: Celebrating Cambridge Cluster

It is our great pleasure at Cellestial Health to be recognised alongside our outstanding peers in the Cambridge ecosystem at the annual #Killer50 2026 event by Business Weekly.We will strive to continue delivering advancements in the treatment of brain disorders for the benefit of patients and the scientific community. With gratitude, always 🙏 About #Killer50:Organised…

Cellestial Health Joins ET Capital Portfolio and Secures Strategic Support

27th of April 2026; Cambridge, UK Cellestial Health, a biopharmaceutical company developing a new class of drugs for Parkinson’s which affects over 10 million people in the world, is pleased to have recently joined the portfolio of the Cambridge Venture Index Fund (CVIF) of ET Capital – a fund supporting diversified deep science companies spinning out…

One Nucleus Awards Gala

Last Thursday 19th of March brought the UK-wide life sciences ecosystem leaders together for a very special occasion of the #ONAwards26 celebration at No.11 Cavendish Square in London. It was a great honour to have the project between Cellestial and The University of Manchester, supported by a Parkinson’s UK grant, recognised as one of the finalist entries in the “Best Industry and…

Best Industry and Not for Profit Collaboration: Finalists

The annual One Nucleus Awards dinner celebrates the excellence of the diverse Life Sciences sector, recognising all parts of the community. One Nucleus believe that it is the interactions and dynamics of the entire ecosystem that lead to successful value and impact creation, the vision that resonates with our team’s. This year, the collaboration between…

Genesis 2025: Current State of Field and De-Risking

The annual Genesis 2025 conference by One Nucleus on Tuesday 3rd of December brought the Life Sciences community together once again, this time under the theme of “𝘔𝘢𝘹𝘪𝘮𝘪𝘴𝘪𝘯𝘨 𝘙𝘦𝘵𝘶𝘳𝘯𝘴 𝘰𝘯 𝘓𝘪𝘧𝘦 𝘚𝘤𝘪𝘦𝘯𝘤𝘦 𝘐𝘯𝘯𝘰𝘷𝘢𝘵𝘪𝘰𝘯”. Dr Nat Hastings delivered a concise presentation on the latest developments at Cellestial Health alongside an array of brilliant companies including LYEONS Neurotech, GutSee Health, and ikarovec, and Martyn Postle actively participated in the networking sessions. The field…

Cellestial Health officially opens Seed funding round

On Monday 17th of November, at the LSX Investival 2025 and at the start of the Jeffries week in London, Dr Nat Hastings (CEO) and Dr Peter Bach (Head of Drug Development) of Cellestial Health have officially opened the Seed fundraise. This follows on from a strong year post-Pre-Seed funding, featuring:✦ Proof-of-concept studies in disease-relevant…

Dazzling Dinner with Cambridge Independent

On Thursday 25th of September Cambridge Independent hosted a Gala dinner to celebrate the 2025 edition of the #CIBusinessAwards at King’s College, Cambridge. The event celebrated a range of local businesses from all sectors, from property management to educational opportunities. It is not easy to stand out in such a diverse environment, and in a…

New Chapter for the Kingdom of Saudi Arabia

On October 1-2, King Abdullah International Medical Research Center (KAIMRC) in partnership with J.P. Morgan Asset Management and the Ministry of Investment (MISA) welcomed 10 global finalists startup companies as well as experts from the biotech and pharmaceutical industry in Riyadh at the #LSIF2025, hosted at #KSAUHS Convention Centre.This event supports the goal of SaudiArabia…

Parkinson’s UK: Further Funding for Pioneering Approach

Parkinson’s UK awarded Cellestial Health £55,000 to continue exploring networks of brain cells that may hold answers for new treatments for Parkinson’s. There are many different types of cells in the brain. We know that in Parkinson’s, brain cells that produce dopamine become damaged and start to die over time. However, it’s possible that other…

Tag: News